This trial is evaluating whether Magrolimab will improve 3 primary outcomes and 9 secondary outcomes in patients with Carcinoma, Squamous Cell. Measurement will happen over the course of First Dose up to 21 days.
This trial requires 230 total participants across 10 different treatment groups
This trial involves 10 different treatments. Magrolimab is the primary treatment being studied. Participants will be divided into 9 treatment groups. There is no placebo group. The treatments being tested are in Phase 2 and have already been tested with other people.
"This case illustrates, in our opinion, the possibility of cure in this type of tumour with only minimal treatment. However, in addition to the local tumour control, adjuvant treatment is important. If the possibility of cure is to be maintained with minimal treatment, close follow-up of the patient and the surgeon is required. We believe this case should serve to provide surgeons with an awareness of the current advances in oral oncology, which have had an influence on the prognosis of OSCC." - Anonymous Online Contributor
"3.0 million people in the United States experience an incident oral cancer diagnosis each year. These people experience an 8.6% mortality from the disease and a 30.9% 5 year survival rate. The lifetime risk of oral cancer in the United States is 4%. Oral cancer disproportionately affects African-American and Latino populations. The annual number of new cases in the United States that are not attributed to tobacco or alcohol use is 8.5%." - Anonymous Online Contributor
"Oral SCC is a multifaceted disease. Over 80% of cancers occur at the site of first contact, which suggests an environmental risk factor for its development. Current smokers and second-hand smoke exposure were associated with increased risk of developing OSCC. Further research is needed to identify more precisely the factors that modify risk for SCC and OSCC." - Anonymous Online Contributor
"Osteoperiostitis secondary to radiation therapy with/or chemotherapy presents common treatments for oral cancer. A new treatment, hyperbaric oxygen therapy (HBOT), has been used with some success. HBOT is a novel treatment that can be used concurrently on a more aggressive form of treatment. The mechanism of action is not clear, but HBOT may interfere with growth and spread of cancer cells in the bone microenvironment. Clinical trials have shown it to be safe and a benefit option for a subset of patients. We recommend HBOT as an alternative treatment option for oral squamous cell carcinoma." - Anonymous Online Contributor
"It is difficult to diagnose early stage ESCC or SCC of the oropharynx in the early stages of carcinoma because the symptoms are not evident until the tumor is in advanced stages. The most important symptom is numbness or paresthesia affecting the head and neck region. In addition, patients with advanced stages or who have undergone radiotherapy are diagnosed late, making it almost impossible to get definitive treatment before the disease progresses to advanced and life-threatening stages." - Anonymous Online Contributor
"The incidence of OSCC in Japan was estimated at 7,090 per 100,000 population. OSCC is one of the 10 most common cancers in Japan. It occurs more frequently in the elderly and is of the lip and nasal cavity type. The most important risk factors are alcohol and smoking. The survival of OSCC patients has improved with progress in medical treatment over the last decades, but they remain unsatisfactorily distributed between socioeconomic classes." - Anonymous Online Contributor
"Magrolimab provided significant improvements in QOL for patients with HNSCC. Although there are a number of factors (such as poor prognosis, non-smokers, or pain) that could have affected the study's outcome, these factors are also factors that many patients face with HNSCC. Magrolimab therefore may have a significant impact on QOL for patients with HNSCC." - Anonymous Online Contributor
"Oral SCC incidence increases after age 40, but the percentage of cases in the 40- to 50-year-old age group remains higher than all other reported studies. Overall, the incidence is lowest in individuals younger than 20 years; the average age at diagnosis is lower for men than women. The oral SCC-related deaths are at least 2 years earlier in men compared to women. The age-adjusted overall survival in men is lower than in women. The incidence of oral SCC may be related to socio-economic status and smoking, particularly among women." - Anonymous Online Contributor
"Patients receiving magrolimab have significantly fewer lesions and greater lesion size reduction. Although, our results have not demonstrated a statistically significant difference in response rate between placebo and magrolimab, our data suggest further investigation is warranted. Magrolimab has been shown to have an active role in the treatment of cancer with a favorable side effect profile. In a recent study, findings shows magrolimab can be a first line chemotherapeutic agent in cancer treatment." - Anonymous Online Contributor
"Magrolimab seems to be effective in decreasing recurrence after chemoradiotherapy for SCC in the head and neck. Additional studies are needed to evaluate the optimal dosing, route of administration, dose or regimen in order to attain maximal tumor response, tolerability and safety." - Anonymous Online Contributor
"Magrolimab may be a promising candidate for the treatment of advanced oral squamous cell carcinomas. Further study should be carried out before any conclusions can be made regarding its use in different clinical settings." - Anonymous Online Contributor
"The severity of SCC was not associated temporally, with the location of SCC, or with smoking prevalence during the lifetime of patients who were eligible for this study. Patients receiving chemotherapy in situ (or post-treatment) had higher grades than those who had not received chemotherapy in situ (and those who had received it prior to referral to this study had a higher grade than those who had not received chemotherapy in situ). The study team did not anticipate, or discuss, the potential for chemotherapy to be associated with higher severity of disease. Results from a recent paper cannot confirm a causal relationship between chemotherapy and disease severity because of the presence of confounding." - Anonymous Online Contributor